GlassScriptPhysician profile
Colleen Mccormick
NPI 1740362052
$28,734.99
in general payments reported to CMS, 2019-2025
16 companies · $124 in 2025
The $124 reported for 2025 was less than what a typical Obstetrics & Gynecology provider received nationally (typical 2025 total: $158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $9,789 · 2020: $5,716 · 2021: $3,611 · 2022: $2,922 · 2023: $6,411 · 2024: $161 · 2025: $124.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $6,400 · Food and Beverage: $285 · Education: $10.85.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $6,400.00 |
| Food and Beverage | $284.57 |
| Education | $10.85 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $16,025.00 | 2020-2023 | Zejula, Jemperli |
| Astrazeneca Pharmaceuticals LP | $9,471.66 | 2019-2020 | |
| Clovis Oncology, INC. | $1,750.00 | 2020 | |
| Tesaro, INC. | $508.04 | 2019 | |
| Merck Sharp & Dohme LLC | $332.88 | 2019-2023 | Keytruda |
| Genmab U.S., INC. | $246.62 | 2022-2024 | Tivdak |
| Ethicon US, LLC | $132.06 | 2024-2025 | Enseal X1, Echelon Flex, Enseal |
| Foundation Medicine, INC. | $117.00 | 2019 | |
| Medical Device Business Services, INC. | $86.95 | 2019 | |
| Seagen INC. | $36.48 | 2021 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $28.30 | 2025 | Lifevest |
5 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Colleen Mccormick listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.